Politics
Personalised medicine to relieve the health service
Smaller patient groups and targeted treatments are the future of cancer care in Norway.
Cancer Crosslinks 2025: Meet the speakers
Introducing the prominent experts speaking at Oslo Cancer Cluster’s landmark conference.
Sign up for the onsite version in Oslo Cancer Cluster Innovation Park or attend digitally. Please visit www.cancercrosslinks.com
Published
Jan 13, 2025
Author
Wenche Gerhardsen
Category
Event
The speakers at Cancer Crosslinks 2025 shape an inspiring scientific programme.
Join us on January 23 as leading international experts will share their insights on the latest advancements in translational cancer research and innovations.
Advances in tumour-agnostic therapies
Vivek Subbiah, MD, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute (SCRI) in Nashville, USA, will open the conference’s scientific programme with an inspiring lecture on Breaking Barriers in Oncology with Tumor-Agnostic Drug Development.
In his role at the Sarah Cannon Research Institute, Dr Subbiah oversees nine drug development units and leads the expansion of early-phase capabilities and programmes across the institute's growing research network. He also serves as a treating physician and has been principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials.
The second speaker of the day is Ruth Plummer, Clinical Professor of Experimental Cancer Medicine, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Director of Sir Bobby Robson Cancer Trials Research Centre, Newcastle, UK. In her keynote, Prof. Plummer will address the question: Can precision medicine deliver histology-independent drug discovery?
The focus of Professor Plummer’s research is first in human clinical trials, running a busy early phase trials practice which includes studies with novel small molecules, antibodies, immunotherapies and cellular therapies. She has taken multiple agents targeting DNA repair into the clinic, including the first-in-class PARP and ATR inhibitors. Her practice is in skin cancer, treating all types of melanomas with systemic therapies.
Join us
Sign up and join us in person or digitally. On the conference website, you will find the complete programme for 23 January 2025.
Our sponsors
Cancer Crosslinks is kindly sponsored by Oslo Cancer Cluster members Bristol Myers Squibb and Kite, A Gilead Company.
Cell therapies
During the second session on cell therapies, Magnus Essand, Professor at Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden will share his work on Arming CAR-T cells for potent bystander responses in lymphoma and glioblastoma.
Next on the programme is Inge Marie Svane, Professor, MD, Director, National Center for Cancer Immune Therapy – CCIT-DK, Department of Oncology, Herlev Hospital, Copenhagen University, Denmark. Professor Svane will further dive into T-cell therapies with a talk entitled Prime time for adoptive T-cell therapy for metastatic melanoma.
Digital innovations
Following a break, Ingrid Stenstadvold Ross, Secretary General at the Norwegian Cancer Society, will open the last session with her perspectives on digital innovations for cancer patients: From diagnosis to recovery, how digital innovations are transforming the cancer patient journey.
Joel Hedlund, Data Director at the Center for Medical Image Science and Visualization (CMIV)/Analytic Imaging Diagnostics Arena (AIDA), AIDA Data Hub Lead, Linköping University, Sweden, will conclude the main programme with a presentation on AIDA - A national collaboration arena for clinical innovation in medical imaging diagnostics AI.
